All Posts Tagged With: "LMNX"
(LMNX) Luminex Wraps Up EraGen Buy
Luminex Corporation (LMNX), a developer of biological testing technologies, has completed its previously-announced acquisition of privately-held diagnostic testing company EraGen Biosciences, Inc. for $34...
(LMNX) Luminex MAGPIX Earns Stevie Award for Business
Luminex Corporation (LMNX), a developer of biological testing technologies, has clinched two American Business Awards (“Stevie Awards”) for its flagship MAGPIX analytical instrument. The Stevie Awards...
(LMNX) Luminex Gets EraGen for $34M
Luminex Corporation (LMNX), a developer of biological testing technologies, has forged a definitive agreement to buy Madison, Wisconsin-based privately-held diagnostic testing company EraGen Biosciences,...
(LIFE) Life Technologies Deals with Luminex
Life Technologies Corporation (LIFE) recently entered into a global sales and distribution agreement with Luminex Corporation (LMNX) to...
(LMNX) Luminex Tops Earnings Estimates
Luminex Corporation (LMNX), a developer of biological testing technologies, posted first-quarter fiscal 2011 earnings per share of 11 cents, comfortably beating the Zacks Consensus Estimate of 6 cents and...
(LMNX) Luminex MAGPIX Wins MDEA
Luminex Corporation (LMNX), a developer of biological testing technologies, recently received the prestigious Medical Design Excellence Award (“MDEA”) for its MAGPIX analytical instrument. MDEA, organized...
(LMNX) Luminex Corporation – Bear of the Day
We reiterate our Underperform recommendation on Luminex Corp. (LMNX). Earnings for fourth quarter and fiscal 2010 beat the Zacks Consensus Estimates, but profit plummeted year-over-year despite an increase...
(LMNX) Luminex Earns FDA Approval for New Diagnostic Test
Luminex Corporation (LMNX), a developer of biological testing technologies, has commenced the commercial launch of its first pharmacogenetic test following its recent approval by the U.S. Food and Drug Administration...
(LMNX) Luminex Analyst Downgrades Shares to Underperform
We downgrade our recommendation on Luminex Corporation (LMNX) to Underperform following the company’s lower-than-expected third quarter results and a less favorable outlook. Third-quarter fiscal 2010 adjusted...
(LMNX) Luminex Analyst Maintains Neutral Rating
We maintain our Neutral recommendation on Luminex Corp. (LMNX) with a target price of $18.
Luminex boasts of a broad product portfolio. The company’s instrument base consists of the Luminex 100 (LX100),...
(LMNX) Luminex Corporation’s Revenues Expand
Luminex Corp. (LMNX) reported fourth-quarter fiscal 2009 earnings (excluding the release of the valuation allowance) of $5.2 million or 12 cents per share, up from $2 million or 5 cents per share in the year-ago...
(LMNX) Luminex Corporation Upgraded to Neutral
Recently, we upgraded Luminex Corp. (LMNX) to Neutral from Underperform. Our decision to upgrade the stock was based on the company’s wide range of products and its significant international presence. These...
(UNH) Healthcare Stock Review – December 2009 – Industry Outlook
OVERVIEW
The healthcare sector comprises different industries, ranging from managed care organizations, healthcare facilities providers and medical devices manufacturers to biotech and pharmaceutical companies. Consequently, we believe that investors...
(LMNX) Luminex Corporation – Bear of the Day
Luminex Corporation (LMNX) reported a third-quarter loss of $0.6 million or a penny per share as opposed to a net income of $3.2 million or 8 cents per share in the comparable period of 2008. The Zacks Consensus...
(LMNX) Luminex Corporation Posts Loss
Luminex Corporation (LMNX) reported a third-quarter loss of $0.6 million or 1 cent per share as opposed to a net income of $3.2 million or 8 cents in the comparable period of 2008. The Zacks Consensus Estimate...
(LMNX) Luminex Corp – next-year estimate pegged at a whopping 359% earnings growth projection
Luminex Corp. (LMNX) is fresh off the heels of a great quarter in which the company swung into profitability from last year. The next-year estimate is extremely bullish and the company’s share price is rallying.
Company Description
Luminex Corp develops...